LATAM MedTech Insights

This episode of LATAM MedTech Insights dives into a sudden and critical regulatory update from Colombia's INVIMA. Last week's clarification on Unique Device Identification (UDI) for Class IIa devices has created an immediate compliance challenge for manufacturers, requiring a new level of data management and specific submission protocols that have caught many off guard. We break down what the new...

This week on LATAM MedTech Insights, we dissect the impactful new regulations quietly introduced in Chile. Exempt Decree No. 25 has significantly expanded the oversight of the national health authority, the ISP, reshaping the compliance landscape for many medical device manufacturers who previously had an easier path to market. We dive into the specifics of what this decree means for your product...

Last week, Brazil's regulatory landscape for MedTech was redefined. ANVISA, the national health agency, unexpectedly rolled out a stringent new framework mandating advanced cybersecurity and data privacy compliance for all AI-driven medical devices. This sudden move disrupts market-entry plans and forces an immediate re-evaluation of regulatory strategies for companies targeting Latin America's la...

This week, we dissect a game-changing regulatory update from Brazil's ANVISA that directly impacts AI-powered medical devices. Brazil has introduced a mandatory "Algorithm Change Protocol" for all Software as a Medical Device (SaMD), creating a new, complex layer of requirements that surpasses current FDA and EU standards. This change is already causing submission delays for unprepared companies....

This week, we dissect the immediate fallout from Brazil's surprise new regulation, ANVISA RDC 925/2026. This sudden rule change for AI-powered medical software has blindsided many international MedTech companies, creating significant new hurdles for entry into Latin America's largest market. We explore how the mandate for local Brazilian clinical data and stringent LGPD-aligned cybersecurity proto...

Brazil's health regulatory agency, ANVISA, has just released a groundbreaking new framework for Software as a Medical Device (SaMD), creating significant new challenges for global MedTech innovators. This update introduces stricter requirements for clinical data and cybersecurity, tailored specifically to the Brazilian context. This policy shift is forcing international companies to rethink their...

This week, we dive into a major regulatory shift in Latin America's largest market. Brazil's ANVISA has just rolled out a comprehensive and demanding new framework for Software as a Medical Device (SaMD), directly impacting AI-driven diagnostics and digital health platforms. We break down what these changes mean for market access. We explore the challenges through the case of a medical AI company....

In this episode, we dissect the groundbreaking new resolution from Brazil's ANVISA that creates a fast-track approval pathway for AI-powered Software as a Medical Device (SaMD). This regulatory shift is set to drastically reduce time-to-market, from years to mere months, for cutting-edge digital health technologies in Latin America's largest healthcare market. We explore the specific requirements,...

Brazil's regulatory body, ANVISA, has just released its strategic agenda for 2026-2027, signaling the most significant shift in the country's MedTech landscape in years. This isn't just a routine update; it's a complete overhaul of key regulations that will redefine market access for international medical device companies. For prepared firms, this opens the door to streamlined entry into Latin Ame...

In this episode, we dissect the breaking news from Brazil where ANVISA has just released an urgent and aggressive new cybersecurity resolution, RDC 999/2026. This sudden move imposes tight deadlines on both new and existing connected medical devices, forcing manufacturers to quickly adapt or risk losing market access in Latin America's largest market. We explore the immediate impact on internation...

This week on LATAM MedTech Insights, we are tackling the crisis unfolding with Mexico's new digital submission platform for medical devices. COFEPRIS aimed for modernization, but the reality for many manufacturers is a cascade of technical failures and confusing new data regulations that are derailing market entry plans. We dissect what is really happening on the ground in Mexico City. We explore...

This week, we dissect the seismic news from Brazil. ANVISA just launched an accelerated approval pathway for AI-powered medical devices, creating a potential gold rush for MedTech innovators. This episode explores the immense opportunity for rapid market entry and the critical, hidden compliance challenges that come with it. We uncover the stringent new post-market surveillance and data reporting...

Brazil's health regulator, ANVISA, has just shaken up the digital health landscape. A new draft resolution brings critical clarifications for AI-powered medical software, creating a clearer but much stricter pathway to Latin America's largest market. This move could accelerate innovation for some, while creating major new hurdles for others. This episode unpacks the critical details of this regula...

This week, we dive into a game-changing development out of Costa Rica. Long known as a premier manufacturing hub for MedTech, the country just launched the "Medical Device Innovation Pathway" (MDIP), a new accelerated registration process exclusively for locally manufactured devices. This move could redefine market entry strategies across Latin America, offering unprecedented speed but with signif...

This week, we dissect the latest critical guidance from Brazil's ANVISA on RDC 751, a regulation that aligns the country's medical device framework with the EU's MDR. This is more than a policy update. it's a strategic shift that redefines the requirements for market access in Latin America's powerhouse. We explore the immediate impact on technical dossiers, post-market surveillance, and the newly...

This week on LATAM MedTech Insights, we dissect the groundbreaking new regulatory framework released by Brazil's ANVISA for AI-powered medical devices. Announced just last week, this move positions Brazil as a leader in digital health regulation in Latin America, but it also creates significant new hurdles for innovators looking to enter the market. We explore the specific requirements of the new...

This week on LATAM MedTech Insights, we dissect a game-changing update from Brazil's regulatory agency, ANVISA. The validity for medical device registrations has been doubled from five to ten years. This sounds like great news, but it comes with a significant new hurdle: a mandatory mid-cycle compliance review that could catch unprepared companies off guard. We break down what this shift means for...

Last week, Brazil's ANVISA sent shockwaves through the MedTech industry by announcing a hard deadline for transitioning all medical device registrations to the new RDC 751 framework. In this episode, we break down what this sudden enforcement means for foreign manufacturers, moving beyond the headlines to reveal the hidden complexities and strategic risks. We explore why existing international dos...

Mexico's regulatory authority, COFEPRIS, has just launched its mandatory all-digital submission platform, DigiPRIS. While this move promises to streamline market access, the initial rollout has created significant and unexpected challenges for medical device manufacturers, leading to submission errors, delays, and uncertainty. This episode of LATAM MedTech Insights unpacks the chaotic first week o...

In this episode, we dive into a critical regulatory update from Brazil that is sending shockwaves through the digital health community. Last week, ANVISA unexpectedly released a new instruction specifically targeting AI and Software as a Medical Device (SaMD), creating immediate hurdles for foreign manufacturers. We break down the three core changes involving clinical data, cybersecurity, and algo...

This week, we dive into a sudden and pivotal regulatory shift in Brazil. ANVISA has just launched a new fast-track approval pathway for medium-risk medical devices, a move that could dramatically accelerate market entry. But this opportunity comes with a complex new requirement that is already tripping up unprepared manufacturers. In this episode, we break down exactly what ANVISA's new resolution...

This week, we dissect the critical new amendment to Brazil's RDC 657 software regulations, a move by ANVISA that specifically targets AI and machine learning devices. The update introduces complex new requirements for clinical validation, post-market changes, and cybersecurity, significantly raising the bar for market entry. We explore what these changes mean for MedTech manufacturers, why Brazil...

This week, we dissect breaking news from Brazil. ANVISA, the national health regulatory agency, has just launched a new fast-track pilot program for AI-powered medical software. This move could slash market entry timelines in half, but it comes with a host of new, complex requirements that could trap unprepared companies. We explore the specific opportunities this creates for MedTech innovators in...

Brazil's ANVISA just launched a new fast-track approval process for AI medical software, a huge opportunity for MedTech innovators. However, this golden ticket comes with a major catch: a strict data localization law that could derail market entry plans for unprepared international companies. This episode of LATAM MedTech Insights unpacks the new resolution and explores the critical strategic deci...

This week on LATAM MedTech Insights, we dissect the seismic shift in Brazil's regulatory landscape. Last week, ANVISA issued an unexpected technical note on clinical evaluation requirements under RDC 751, fundamentally altering the path to market for many international device manufacturers. We explore the end of the 'easy' equivalence route based on CE or FDA clearance and what this means for your...